NCT04406623 is a Phase 1 clinical trial of SL-172154 in Ovarian Cancer, sponsored by Shattuck Labs, Inc..

Who is sponsoring NCT04406623?

NCT04406623 is sponsored by Shattuck Labs, Inc..

What drugs are being tested in NCT04406623?

Interventions in NCT04406623: SL-172154.

What condition does NCT04406623 study?

NCT04406623 studies Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma.

Is NCT04406623 still recruiting?

NCT04406623 is currently completed. Last updated 30 January 2025.

Are results published for NCT04406623?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-01-30 · How we verify

NCT04406623

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer

Completed Phase 1 Results posted Last updated 30 January 2025

What this trial tests

Phase 1 trial testing SL-172154 in Ovarian Cancer in 27 participants. Completed in 2 February 2023.

Timeline

29 June 2020

Primary endpoint
2 February 2023

2 February 2023

Quick facts

Lead sponsor	Shattuck Labs, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	29 June 2020
Primary completion	2 February 2023
Estimated completion	2 February 2023
Sites	6 locations across United States

Drugs / interventions tested

SL-172154 — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →
Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →
Primary Peritoneal Carcinoma — all drugs for Primary Peritoneal Carcinoma →

Sponsor

Shattuck Labs, Inc. — full company profile →

Who can join

18 and older, female only, with Ovarian Cancer or Fallopian Tube Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Safety Profile of SL-172154 Primary · From Day 1 to 90 days after Last Dose of SL-172154

Number of participants with treatment emergent adverse events

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	3
SL-172154 (0.3 mg/kg)	6
SL-172154 (1.0 mg/kg)	4
SL-172154 (3.0 mg/kg)	9
SL-172154 (10.0 mg/kg)	5

Maximum Tolerated Dose (MTD) of SL-172154 Primary · From Day 1 to 90 days after Last Dose of SL-172154

Number of participants with dose limiting toxicities (DLTs)

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	0
SL-172154 (0.3 mg/kg)	0
SL-172154 (1.0 mg/kg)	0
SL-172154 (3.0 mg/kg)	0
SL-172154 (10.0 mg/kg)	1

Recommended Phase 2 Dose (RP2D) for SL-172154 Secondary · Approximately 24 months

Based on review of all data, including safety, tolerability, PK, antitumor activity, and PD effects

Group	Value	95% CI
SL-172154	3.0

Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 Secondary · Approximately 24 months

Number of participants with an objective response per investigator assessment according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1). Objective response includes complete response (disappearance of all target lesions) and partial response (\>/= 30% decrease in the sum of the longest diameter of target lesions).

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	0
SL-172154 (0.3 mg/kg)	0
SL-172154 (1.0 mg/kg)	0
SL-172154 (3.0 mg/kg)	0
SL-172154 (10.0 mg/kg)	0

Immunogenicity to SL-172154 Secondary · Approximately 24 months

Number of participants with positive anti-drug antibody (ADA) titer, sustained ADA response (positive ADA in \>/= 2 samples without reverting to negative ADA or positive ADA in the last sample), or persistent ADA response (positive ADA in \>/= 2 samples where the first and last samples are \>/= 16 weeks apart, or positive ADA in the last sample, or only one sample but \< 16 weeks before a negative last sample).

Positive anti-drug antibody titer

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	1
SL-172154 (0.3 mg/kg)	4
SL-172154 (1.0 mg/kg)	2
SL-172154 (3.0 mg/kg)	3
SL-172154 (10.0 mg/kg)	3

Sustained ADA response

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	1
SL-172154 (0.3 mg/kg)	3
SL-172154 (1.0 mg/kg)	2
SL-172154 (3.0 mg/kg)	1
SL-172154 (10.0 mg/kg)	1

Persistent ADA response

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	0
SL-172154 (0.3 mg/kg)	1
SL-172154 (1.0 mg/kg)	1
SL-172154 (3.0 mg/kg)	1
SL-172154 (10.0 mg/kg)	0

Maximum Serum Concentration (Cmax) of SL-172154 Secondary · Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (each cycle = 28 days)

The Cmax is the maximum observed serum concentration of SL-172154 following single and multiple doses

Cycle 1 Day 1

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	117.68	± 31.06
SL-172154 (0.3 mg/kg)	126.33	± 89.20
SL-172154 (1.0 mg/kg)	545.03	± 406.44
SL-172154 (3.0 mg/kg)	4593.19	± 90.34
SL-172154 (10.0 mg/kg)	87509.31	± 51.12

Cycle 1 Day 15

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	59.20	± 29.92
SL-172154 (0.3 mg/kg)	136.96	± 93.93
SL-172154 (1.0 mg/kg)	1772.77	± 111.10
SL-172154 (3.0 mg/kg)	3071.26	± 883.11
SL-172154 (10.0 mg/kg)	50484.31	± 33.38

Cycle 2 Day 1

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	72.96	± 55.09
SL-172154 (0.3 mg/kg)	82.11	± 14.84
SL-172154 (1.0 mg/kg)	1240.25	± 72.61
SL-172154 (3.0 mg/kg)	5219.40	± 151.02
SL-172154 (10.0 mg/kg)	115536.25	± 51.83

Minimum Serum Concentration (Cmin) of SL-172154 Secondary · Cycle 1 Day 15 and Cycle 2 Day 1 (each cycle = 28 days)

The Cmin is the minimum observed serum concentration of SL-172154 following at least one dose

Cycle 1 Day 15

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	0	± NA
SL-172154 (0.3 mg/kg)	0	± NA
SL-172154 (1.0 mg/kg)	0	± NA
SL-172154 (3.0 mg/kg)	0	± NA
SL-172154 (10.0 mg/kg)	0	± NA

Cycle 2 Day 1

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	0	± NA
SL-172154 (0.3 mg/kg)	0	± NA
SL-172154 (1.0 mg/kg)	0	± NA
SL-172154 (3.0 mg/kg)	0	± NA
SL-172154 (10.0 mg/kg)	0	± NA

Time at Which Maximum Concentration of SL-172154 is Observed (Tmax) Secondary · Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (each cycle = 28 days)

The Tmax is the time at which the maximum concentration of SL-172154 is observed following single and multiple doses

Cycle 1 Day 1

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	0.5	0.5 – 0.5
SL-172154 (0.3 mg/kg)	0.56	0.5 – 1.6
SL-172154 (1.0 mg/kg)	0.55	0.5 – 2.6
SL-172154 (3.0 mg/kg)	2.53	1.1 – 5.0
SL-172154 (10.0 mg/kg)	3.43	2.0 – 5.0

Cycle 1 Day 15

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	0.53	0.5 – 0.7
SL-172154 (0.3 mg/kg)	0.54	0.5 – 2.3
SL-172154 (1.0 mg/kg)	0.57	0.5 – 0.6
SL-172154 (3.0 mg/kg)	2.06	1.1 – 2.8
SL-172154 (10.0 mg/kg)	3.6	2.0 – 3.6

Cycle 2 Day 1

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	0.5	0.5 – 0.5
SL-172154 (0.3 mg/kg)	0.53	0.5 – 1.1
SL-172154 (1.0 mg/kg)	0.55	0.5 – 1.5
SL-172154 (3.0 mg/kg)	2.08	1.0 – 4.1
SL-172154 (10.0 mg/kg)	1.97	1.9 – 2.0

Area Under the Serum Concentration-time Curve (AUC) Secondary · Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (each cycle = 28 days)

The AUC is the area under the serum concentration time curve following single and multiple doses of SL-172154. AUC (0-last; from time 0 to the last quantifiable concentration) is reported for C1D1 and AUC (tau; over a dosing interval) is reported for C1D15 and C2D1.

Cycle 1 Day 1

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	NA	± NA
SL-172154 (0.3 mg/kg)	143.54	± 7.74
SL-172154 (1.0 mg/kg)	639.40	± 18.47
SL-172154 (3.0 mg/kg)	7062.14	± 81.59
SL-172154 (10.0 mg/kg)	200095.11	± 78.74

Cycle 1 Day 15

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	NA	± NA
SL-172154 (0.3 mg/kg)	NA	± NA
SL-172154 (1.0 mg/kg)	NA	± NA
SL-172154 (3.0 mg/kg)	13030.1	± 27.31
SL-172154 (10.0 mg/kg)	133015.0	± NA

Cycle 2 Day 1

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	NA	± NA
SL-172154 (0.3 mg/kg)	NA	± NA
SL-172154 (1.0 mg/kg)	NA	± NA
SL-172154 (3.0 mg/kg)	6103.60	± 130.09
SL-172154 (10.0 mg/kg)	236849.02	± 91.90

Terminal Elimination Half-life (t1/2) Secondary · Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (each cycle = 28 days)

Terminal elimination half-life (t1/2) of SL-172154

Cycle 1 Day 1

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	NA	± NA
SL-172154 (0.3 mg/kg)	0.50	± NA
SL-172154 (1.0 mg/kg)	0.37	± 0.056
SL-172154 (3.0 mg/kg)	0.75	± 0.710
SL-172154 (10.0 mg/kg)	0.86	± 0.278

Cycle 1 Day 15

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	NA	± NA
SL-172154 (0.3 mg/kg)	NA	± NA
SL-172154 (1.0 mg/kg)	NA	± NA
SL-172154 (3.0 mg/kg)	0.32	± 0.132
SL-172154 (10.0 mg/kg)	0.71	± NA

Cycle 2 Day 1

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	NA	± NA
SL-172154 (0.3 mg/kg)	NA	± NA
SL-172154 (1.0 mg/kg)	NA	± NA
SL-172154 (3.0 mg/kg)	0.36	± 0.158
SL-172154 (10.0 mg/kg)	1.30	± 0.477

Clearance (CL) Secondary · Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (each cycle = 28 days)

Clearance of SL-172154

Cycle 1 Day 1

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	NA	± NA
SL-172154 (0.3 mg/kg)	110.64	± NA
SL-172154 (1.0 mg/kg)	121.22	± 46.305
SL-172154 (3.0 mg/kg)	35.73	± 25.580
SL-172154 (10.0 mg/kg)	4.13	± 2.605

Cycle 1 Day 15

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	NA	± NA
SL-172154 (0.3 mg/kg)	NA	± NA
SL-172154 (1.0 mg/kg)	NA	± NA
SL-172154 (3.0 mg/kg)	15.15	± 2.650
SL-172154 (10.0 mg/kg)	4.44	± NA

Cycle 2 Day 1

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	NA	± NA
SL-172154 (0.3 mg/kg)	NA	± NA
SL-172154 (1.0 mg/kg)	NA	± NA
SL-172154 (3.0 mg/kg)	44.88	± 48.958
SL-172154 (10.0 mg/kg)	3.17	± 1.637

Volume of Distribution Secondary · Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (each cycle = 28 days)

Volume of distribution of SL-172154

Cycle 1 Day 1

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	NA	± NA
SL-172154 (0.3 mg/kg)	79.83	± NA
SL-172154 (1.0 mg/kg)	64.28	± 28.528
SL-172154 (3.0 mg/kg)	28.46	± 17.148
SL-172154 (10.0 mg/kg)	4.84	± 2.982

Cycle 1 Day 15

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	NA	± NA
SL-172154 (0.3 mg/kg)	NA	± NA
SL-172154 (1.0 mg/kg)	NA	± NA
SL-172154 (3.0 mg/kg)	7.32	± 4.187
SL-172154 (10.0 mg/kg)	4.53	± NA

Cycle 2 Day 1

Group	Value	95% CI
SL-172154 (0.1 mg/kg)	NA	± NA
SL-172154 (0.3 mg/kg)	NA	± NA
SL-172154 (1.0 mg/kg)	NA	± NA
SL-172154 (3.0 mg/kg)	32.01	± 49.282
SL-172154 (10.0 mg/kg)	5.62	± 3.337

Adverse events — posted to ClinicalTrials.gov

Time frame: Subjects were followed continuously for all AEs starting when a subject signed the informed consent form, throughout the course of treatment, and for 90 days after the last dose of study treatment, an average of 10.5 weeks.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

SL-172154 (0.1 mg/kg)

Serious: 1/3 (33%)

Deaths: 2/3

SL-172154 (0.3 mg/kg)

Serious: 0/6 (0%)

Deaths: 5/6

SL-172154 (1.0 mg/kg)

Serious: 1/4 (25%)

Deaths: 3/4

SL-172154 (3.0 mg/kg)

Serious: 2/9 (22%)

Deaths: 2/9

SL-172154 (10.0 mg/kg)

Serious: 2/5 (40%)

Deaths: 1/5

Serious adverse events (5 terms)

Reaction	System	SL-172154 (0.1 mg/kg)	SL-172154 (0.3 mg/kg)	SL-172154 (1.0 mg/kg)	SL-172154 (3.0 mg/kg)	SL-172154 (10.0 mg/kg)
embolism	Vascular disorders	—	—	—	—	—
sepsis	Infections and infestations	—	—	—	—	—
large intestine infection	Infections and infestations	—	—	—	—	—
lower gastrointestinal haemorrhage	Gastrointestinal disorders	—	—	—	—	—
small intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—

Other adverse events (46 terms — click to expand)

Reaction	System	SL-172154 (0.1 mg/kg)	SL-172154 (0.3 mg/kg)	SL-172154 (1.0 mg/kg)	SL-172154 (3.0 mg/kg)	SL-172154 (10.0 mg/kg)
infusion related reaction	Injury, poisoning and procedural complications	—	—	—	—	—
fatigue	General disorders	—	—	—	—	—
nausea	Gastrointestinal disorders	—	—	—	—	—
back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—
arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—
hyperglycaemia	Metabolism and nutrition disorders	—	—	—	—	—
constipation	Gastrointestinal disorders	—	—	—	—	—
diarrhoea	Gastrointestinal disorders	—	—	—	—	—
hypoalbuminaemia	Metabolism and nutrition disorders	—	—	—	—	—
AST increased	Investigations	—	—	—	—	—
blood LDH increased	Investigations	—	—	—	—	—
pruritis	Skin and subcutaneous tissue disorders	—	—	—	—	—
hypertension	Vascular disorders	—	—	—	—	—
anaemia	Blood and lymphatic system disorders	—	—	—	—	—
lymphopenia	Blood and lymphatic system disorders	—	—	—	—	—
sinus tachycardia	Cardiac disorders	—	—	—	—	—
hyperbilirubinaemia	Hepatobiliary disorders	—	—	—	—	—
abdominal distension	Gastrointestinal disorders	—	—	—	—	—
abdominal pain	Gastrointestinal disorders	—	—	—	—	—
vomiting	Gastrointestinal disorders	—	—	—	—	—
dyspepsia	Gastrointestinal disorders	—	—	—	—	—
flatulence	Gastrointestinal disorders	—	—	—	—	—
chills	General disorders	—	—	—	—	—
pain	General disorders	—	—	—	—	—
oedema peripheral	General disorders	—	—	—	—	—
muscle spasms	Musculoskeletal and connective tissue disorders	—	—	—	—	—
myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—
neck pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—
decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—
dehydration	Metabolism and nutrition disorders	—	—	—	—	—
hyperkalaemia	Metabolism and nutrition disorders	—	—	—	—	—
hypomagnesaemia	Metabolism and nutrition disorders	—	—	—	—	—
hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—
hypophosphataemia	Metabolism and nutrition disorders	—	—	—	—	—
ALT increased	Investigations	—	—	—	—	—
activated PTT prolonged	Investigations	—	—	—	—	—
headache	Nervous system disorders	—	—	—	—	—
rash maculo-papular	Skin and subcutaneous tissue disorders	—	—	—	—	—
embolism	Vascular disorders	—	—	—	—	—
thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—

Most-reported serious reactions: embolism, sepsis, large intestine infection, lower gastrointestinal haemorrhage, small intestinal obstruction.

Data from ClinicalTrials.gov NCT04406623 adverse events section.

Sponsor's own description

This is a Phase 1 first in human, open label, multi-center, dose escalation study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-172154 in subjects with ovarian cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

CD47-SIRPα-targeted therapeutics: status and prospects.
Maute R, Xu J, Weissman IL. · · 2022 · cited 105× · PMID 35754851 · DOI 10.1016/j.iotech.2022.100070
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments.
Xu J, Ding L, Mei J, Hu Y, et al · · 2025 · cited 89× · PMID 40850976 · DOI 10.1038/s41392-025-02325-5
CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies.
Bullock TNJ. · · 2022 · cited 89× · PMID 34282297 · DOI 10.1038/s41423-021-00734-4
CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies.
Bouwstra R, van Meerten T, Bremer E. · · 2022 · cited 82× · PMID 35908284 · DOI 10.1002/ctm2.943
Tumor-Associated Macrophages in Gliomas-Basic Insights and Treatment Opportunities.
Andersen JK, Miletic H, Hossain JA. · · 2022 · cited 60× · PMID 35267626 · DOI 10.3390/cancers14051319
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma.
Truxova I, Cibula D, Spisek R, Fucikova J. · · 2023 · cited 54× · PMID 36822672 · DOI 10.1136/jitc-2022-005968
Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective.
Chen YC, Shi W, Shi JJ, Lu JJ. · · 2022 · cited 50× · PMID 34609596 · DOI 10.1007/s00432-021-03815-z
Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data.
Son J, Hsieh RC, Lin HY, Krause KJ, et al · · 2022 · cited 42× · PMID 36439116 · DOI 10.3389/fimmu.2022.1027235

Verify or expand the search:

Other trials of SL-172154

Trials testing the same drug.

NCT05275439 — Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML · Phase 1 · terminated

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Shattuck Labs, Inc. trials

Trials by the same sponsor.

NCT05483933 — Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers · Phase 1 · completed
NCT05275439 — Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML · Phase 1 · terminated
NCT04502888 — Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin · Phase 1 · terminated
NCT03894618 — SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04406623 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shattuck Labs, Inc.
Last refreshed: 30 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04406623.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT04406623

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (5 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of SL-172154

Other recruiting trials for Ovarian Cancer

Other Shattuck Labs, Inc. trials

Verify against primary sources